Bacterial Conjunctivitis in Children: Antibacterial Treatment Options in an Era of Increasing Drug Resistance

Leibowitz HM The red eye. N Engl J Med. 2000;343: 345-351.

Morrow GL , Abbott RL Conjunctivitis. Am Fam Physician. 1998;57:735-746.

Patel PB , Diaz MC , Bennett JE , Attia MW Clinical features of bacterial conjunctivitis in children. Acad Emerg Med. 2007;14:1-5.

Sheikh A. , Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review . Br J Gen Pract. 2001;51:473-477.

Teoh DL , Reynolds S. Diagnosis and management of pediatric conjunctivitis. Pediatr Emerg Care. 2003;19:48-55.

Bodor FF Conjunctivitis-otitis syndrome. Pediatrics. 1982;69:695-698.

Rose P. Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin Pharmacother. 2007;8:1903-1921.

Sheikh A. , Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis. Br J Gen Pract. 2005:55:962-964.

Harbarth S. , Samore MH Antimicrobial resistance determinants and future control. Emerg Infect Dis. 2005;11: 794-801.

Asbell PA , Colby KA , Deng S. , et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008;145:951-958.

Asbell PA , Sahm DF , Shaw M. , Draghi DC , Brown NP Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005. J Cataract Refract Surg. 2008;34:814-818.

Block SL , Hedrick J. , Tyler R. , et al. Increasing bacterial resistance in pediatric acute conjunctivitis (1997-1998). Antimicrob Agents Chemother. 2000;44:1650-1654.

Sheikh A. , Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2006;19(2):CD001211.

Bodor FF Systemic antibiotics for the treatment of the conjunctivitis otitis media syndrome. Pediatr Infect Dis J. 1989;8:287-290.

Mah FS New antibiotics for bacterial infections. Ophthalmol Clin North Am. 2003;16:11-27.

Wald ER , Greenberg D. , Hoberman A. Short-term oral cefixime therapy for treatment of bacterial conjunctivitis . Pediatr Infect Dis J. 2001;20:1039-1042.

Cavuoto K. , Zutshi D. , Karp CL , Miller D. , Feuer W. Update on bacterial conjunctivitis in South Florida. Ophthalmology . 2008;115:51-56.

Gwon A. ; for the Ofloxacin Study Group. Topical ofloxacin compared with gentamicin in the treatment of ocular infection . Br J Ophthalmol. 1992;76:714-718.

Cagle G. , Davis S. , Rosenthal A. , Smith J. Topical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter study. Curr Eye Res. 1981;1:523-534.

Timewell RM , Rosenthal AL , Smith JP , Cagle GD Safety and efficacy of tobramycin and gentamicin in the treatment of external ocular infections of children. J Pediatr Ophthalmol Strabismus. 1983;20:22-26.

Abelson MB , Heller W. , Shapiro AM , Si E. , Hsu P. , Bowman LM ; AzaSite Clinical Study Group. Clinical cure of bacterial conjunctivitis with azithromycin 1%; vehicle-controlled, double-masked clinical trial. Am J Ophthalmol. 2008;145:959-965.

Ohnsman C. , Ritterband D. , O’Brien T. , Girgis D. , Kabat A. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis. Curr Med Res Opin. 2007;23:2241-2249.

Kaliamurthy J. , Nelson Jesudasan CA , Parmar P. , Kalavathy CM , Thomas PA Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics. Ophthalmic Res. 2005;37: 117-122.

Keating GM Levofloxacin 0.5% ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery. Drugs. 2009;69:1267-1286.

Karpecki P. , DePaolis M. , Hunter JA , et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study . Clin Ther. 2009;31:514-526.

McDonald MB , Protzko EE , Brunner LS , et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis Ophthalmology . 2009;116: 1615-1623.

Comstock TL , Paterno MR , Lynch JA , Usner DW , Pichichero, ME Efficacy and safety of besifloxacin ophthalmic suspension, 0.6% in pediatric patients with bacterial conjunctivitis. Pediatr Drugs. 2010;12:105-112.

Fukuda H. , Kishii R. , Takei M. , Hosaka M. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae . Antimicrob Agents Chemother. 2001;45:1649-1653.

McDonald MB , Blondeau JM , DeCory HH , et al. Multidrug-resistant strains in clinical trials of besifloxacin in the treatment of bacterial conjunctivitis. Poster presented at: American Academy of Ophthalmology Annual Meeting; November 8-11, 2008; Atlanta, GA.

Chou TM , Gigliotti F. , Lichtenstein SJ Bacterial conjunctivitis: setting a course for containment and cure. Contemp Pediatr. 2004;21:2-8.

Jacob SE , James WD From road rash to top allergen in a flash: bacitracin. Dermatol Surg. 2004;30(4 Pt 1): 521-524.

Roberts C. Comparison of the ocular comfort of ofloxacin 0.3% ophthalmic solution and lubricant eye drops. Clin Pediatr. 2002;41:151-154.

Granet D. , Lichtenstein SJ , Onofrey B. , Katz JA An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite. Clin Ophthalmol. 2007;1: 519-525.